mTOR Overactivation Drives Lung Aging via Cell-Type-Specific Senescence
Mouse study reveals how mTOR activation in different lung cells causes either fibrosis or emphysema, with senolytic treatment reversing damage.
Summary
Researchers generated three mouse models with mTOR overactivation in specific lung cell types — fibroblasts, endothelial cells, or alveolar epithelial cells — by deleting the mTOR inhibitor TSC1. Each model developed distinct lung pathology: fibroblast-targeted deletion caused fibrosis, endothelial deletion caused emphysema, and epithelial deletion caused both. All models showed elevated senescence markers (p16, p21, γH2AX). Treatment with the senolytic drug ABT-263 cleared senescent cells, reduced mTOR signaling, and reversed lung pathology in the transgenic models. However, aged wild-type mice with spontaneous lung disease showed only marginal improvement with ABT-263, suggesting age-related mTOR-driven senescence is only partially reversible.
Detailed Summary
Pulmonary fibrosis and emphysema are devastating age-related lung diseases, but why some individuals develop one condition versus the other has remained poorly understood. This study investigates whether mTOR (mechanistic target of rapamycin) overactivation in specific lung cell populations drives distinct senescence-mediated disease phenotypes, and whether eliminating those senescent cells can reverse the damage.
Using Cre-lox technology, the researchers created three conditional knockout mouse models lacking TSC1 — a key negative regulator of mTORC1 — in fibroblasts/smooth muscle cells (SM22-TSC1⁻/⁻), endothelial cells (PDGF-TSC1⁻/⁻), or alveolar epithelial cells (SPC-TSC1⁻/⁻). Three months post-deletion, all three strains exhibited elevated mTORC1 and mTORC2 activity (elevated pS6K, pAkt-Ser473, pGSK3) and upregulated senescence markers p16, p21, and γH2AX — without any external stressor such as cigarette smoke or radiation.
Strikingly, the resulting lung pathology differed by cell type. SM22-TSC1⁻/⁻ mice developed pulmonary fibrosis, with increased Ashcroft scores, Sirius red collagen staining, and elevated Col1A1, Col3A1, PAI1, and phospho-Smad3. PDGF-TSC1⁻/⁻ mice developed emphysema (increased mean linear intercept) without fibrosis. SPC-TSC1⁻/⁻ mice showed a mixed phenotype — both emphysema and milder fibrosis — with Col1A1 and PAI1 elevated but Col3A1 and pSmad3 selectively absent compared to SM22 mice, indicating fibroblast-driven senescence produces a more severe fibrotic response.
Treatment with ABT-263 (navitoclax), a senolytic that promotes apoptosis of senescent cells by inhibiting Bcl-2 family proteins, reduced senescence markers and increased cleaved caspase-3 in all three models. This was accompanied by reduced mTOR pathway activation and significant reversal of the disease phenotype in each strain — fibrosis resolved in SM22-TSC1⁻/⁻ mice, emphysema improved in PDGF-TSC1⁻/⁻ mice, and both components improved in SPC-TSC1⁻/⁻ mice. The response of individual senescence markers to ABT-263 varied across strains, suggesting cell-type-specific differences in senescence programs.
When the same ABT-263 treatment was applied to naturally aged mice — which showed spontaneous emphysema, fibrosis, and elevated mTOR activity — improvements in lung pathology were only marginal. This suggests that age-accumulated senescence and mTOR-driven lung damage become progressively entrenched and harder to reverse compared to acute, genetically-induced disease. The findings collectively implicate mTOR-mediated, cell-type-specific senescence as a central driver of divergent pulmonary aging phenotypes, while also highlighting the limitations of senolytic strategies in fully reversing established age-related disease.
Key Findings
- Fibroblast-specific mTOR overactivation (SM22-TSC1⁻/⁻) caused pulmonary fibrosis without emphysema in mice.
- Endothelial-specific mTOR overactivation (PDGF-TSC1⁻/⁻) caused emphysema exclusively, not fibrosis.
- Alveolar epithelial mTOR overactivation (SPC-TSC1⁻/⁻) produced a mixed emphysema-fibrosis phenotype.
- Senolytic ABT-263 cleared senescent cells, reduced mTOR signaling, and reversed lung pathology in all three transgenic models.
- ABT-263 only marginally improved lung disease in naturally aged mice, suggesting partial reversibility of age-related mTOR-driven damage.
Methodology
Three conditional knockout mouse strains (SM22-TSC1⁻/⁻, PDGF-TSC1⁻/⁻, SPC-TSC1⁻/⁻) were generated using Cre-lox recombination with tamoxifen or doxycycline induction and analyzed 3 months post-deletion. Lung phenotype was assessed by histology (H&E, Sirius red, elastin staining), Ashcroft scoring, mean linear intercept measurements, and Western blot for fibrosis, emphysema, senescence, and mTOR pathway markers. Senolytic intervention used oral ABT-263 (50 mg/kg/day) initiated 9 weeks after TSC1 deletion.
Study Limitations
The study uses constitutive genetic TSC1 deletion rather than pharmacological mTOR activation, which may not fully recapitulate human disease mechanisms. ABT-263 eliminates all senescent cells non-selectively, making it difficult to isolate effects on TSC1-deficient cells specifically. The marginal benefit in aged mice limits translational confidence for senolytic therapy in established age-related pulmonary disease.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: